Brentuximab Vedotin: A CD30-Directed Antibody-Cytotoxic Drug Conjugate
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Brentuximab Vedotin: A CD30-Directed Antibody-Cytotoxic Drug Conjugate
Authors
Keywords
-
Journal
PHARMACOTHERAPY
Volume 33, Issue 1, Pages 93-104
Publisher
Wiley
Online
2013-01-10
DOI
10.1002/phar.1170
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interim results for the phase II study of panobinostat (LBH589) in patients (Pts) with relapsed/refractory Hodgkin's lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT).
- (2017) A. Sureda et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
- (2012) R. Chen et al. BLOOD
- Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation
- (2012) A. K. Gopal et al. BLOOD
- Anaplastic large cell lymphoma, ALK-positive
- (2012) Andrés J.M. Ferreri et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody Conjugate Therapeutics: Challenges and Potential
- (2011) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
- (2011) M. A. Fanale et al. CLINICAL CANCER RESEARCH
- Brentuximab Vedotin (SGN-35)
- (2011) J. Katz et al. CLINICAL CANCER RESEARCH
- CD30-targeted antibody therapy
- (2011) Anas Younes CURRENT OPINION IN ONCOLOGY
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
- (2009) Alison J. Moskowitz et al. BRITISH JOURNAL OF HAEMATOLOGY
- ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
- (2008) K. J. Savage et al. BLOOD
- Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma
- (2007) Yasuhiro Oki et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started